AR052677A1 - Compuesto en la forma racemica (r,s) o en sus formas enantiomericas r y s y sus sales farmacologicamente aceptables - Google Patents
Compuesto en la forma racemica (r,s) o en sus formas enantiomericas r y s y sus sales farmacologicamente aceptablesInfo
- Publication number
- AR052677A1 AR052677A1 ARP060100732A ARP060100732A AR052677A1 AR 052677 A1 AR052677 A1 AR 052677A1 AR P060100732 A ARP060100732 A AR P060100732A AR P060100732 A ARP060100732 A AR P060100732A AR 052677 A1 AR052677 A1 AR 052677A1
- Authority
- AR
- Argentina
- Prior art keywords
- acceptable salts
- pharmacologically acceptable
- racemic form
- enantiomeric forms
- cpt
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 abstract 2
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000003345 hyperglycaemic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000090A ITRM20050090A1 (it) | 2005-03-02 | 2005-03-02 | Derivati dell'acido ammino-butanoico inibitore della cpt. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052677A1 true AR052677A1 (es) | 2007-03-28 |
Family
ID=36090946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100732A AR052677A1 (es) | 2005-03-02 | 2006-02-28 | Compuesto en la forma racemica (r,s) o en sus formas enantiomericas r y s y sus sales farmacologicamente aceptables |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080161395A1 (enExample) |
| EP (1) | EP1853556A1 (enExample) |
| JP (1) | JP2008531613A (enExample) |
| KR (1) | KR20070114197A (enExample) |
| CN (1) | CN101133019A (enExample) |
| AR (1) | AR052677A1 (enExample) |
| AU (1) | AU2006220097B2 (enExample) |
| BR (1) | BRPI0607558A2 (enExample) |
| CA (1) | CA2599165A1 (enExample) |
| EA (1) | EA200701868A1 (enExample) |
| IT (1) | ITRM20050090A1 (enExample) |
| MX (1) | MX2007009007A (enExample) |
| SG (1) | SG159569A1 (enExample) |
| TW (1) | TW200640842A (enExample) |
| WO (1) | WO2006092204A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3144493A1 (en) * | 2006-10-03 | 2008-04-10 | Arbutus Biopharma Corporation | Lipid containing formulations |
| CA2680366C (en) * | 2007-03-09 | 2016-06-21 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
| WO2009015485A1 (en) | 2007-08-01 | 2009-02-05 | University Health Network | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| WO2009132978A1 (en) * | 2008-04-29 | 2009-11-05 | F. Hoffmann-La Roche Ag | 4-dimethylaminobutyric acid derivatives |
| CA2722114A1 (en) | 2008-04-29 | 2009-11-05 | F. Hoffmann-La Roche Ag | 4-trimethylammonio-butyrates as cpt2 inhibitors |
| KR20230041744A (ko) * | 2020-07-17 | 2023-03-24 | 사노피 파스퇴르 | 화학식 -nh-cx-a 또는 -nh-cx-nh-a의 적어도 하나의 말단 라디칼을 포함하는 지질 화합물, 이를 포함하는 조성물 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1299266B1 (it) * | 1998-05-15 | 2000-02-29 | Sigma Tau Ind Farmaceuti | Inibitori reversibili della carnitina palmitoil trasferasi |
| US6822115B2 (en) * | 1999-06-30 | 2004-11-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid |
| CA2680366C (en) | 2007-03-09 | 2016-06-21 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
-
2005
- 2005-03-02 IT IT000090A patent/ITRM20050090A1/it unknown
-
2006
- 2006-02-13 BR BRPI0607558-4A patent/BRPI0607558A2/pt not_active IP Right Cessation
- 2006-02-13 KR KR1020077022098A patent/KR20070114197A/ko not_active Ceased
- 2006-02-13 JP JP2007557357A patent/JP2008531613A/ja not_active Withdrawn
- 2006-02-13 US US11/815,068 patent/US20080161395A1/en not_active Abandoned
- 2006-02-13 EA EA200701868A patent/EA200701868A1/ru unknown
- 2006-02-13 CA CA002599165A patent/CA2599165A1/en not_active Abandoned
- 2006-02-13 SG SG201001512-1A patent/SG159569A1/en unknown
- 2006-02-13 WO PCT/EP2006/001290 patent/WO2006092204A1/en not_active Ceased
- 2006-02-13 EP EP06706901A patent/EP1853556A1/en not_active Withdrawn
- 2006-02-13 MX MX2007009007A patent/MX2007009007A/es not_active Application Discontinuation
- 2006-02-13 CN CNA2006800065461A patent/CN101133019A/zh active Pending
- 2006-02-13 AU AU2006220097A patent/AU2006220097B2/en not_active Ceased
- 2006-02-15 TW TW095105107A patent/TW200640842A/zh unknown
- 2006-02-28 AR ARP060100732A patent/AR052677A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0607558A2 (pt) | 2009-09-15 |
| KR20070114197A (ko) | 2007-11-29 |
| CN101133019A (zh) | 2008-02-27 |
| JP2008531613A (ja) | 2008-08-14 |
| ITRM20050090A1 (it) | 2006-09-03 |
| CA2599165A1 (en) | 2006-09-08 |
| AU2006220097A1 (en) | 2006-09-08 |
| US20080161395A1 (en) | 2008-07-03 |
| MX2007009007A (es) | 2007-09-14 |
| EP1853556A1 (en) | 2007-11-14 |
| EA200701868A1 (ru) | 2008-02-28 |
| TW200640842A (en) | 2006-12-01 |
| AU2006220097B2 (en) | 2011-07-07 |
| WO2006092204A1 (en) | 2006-09-08 |
| SG159569A1 (en) | 2010-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201101037A1 (ru) | Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином | |
| CY1120389T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη | |
| BRPI0911035B8 (pt) | ativadores de pirrolidinona glicoquinase | |
| CR20120019A (es) | Composicion de insulina de accion prolongada | |
| CO6362017A2 (es) | Peptidos antivirales terapeuticos | |
| CR11688A (es) | Compuesto heterociclico | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| PT2359834T (pt) | Tratamento de doentes com hemoglobimúria paroxística noturna por meio de um inibidor de complemento | |
| MX357820B (es) | Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva. | |
| UY32030A (es) | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" | |
| CR11231A (es) | Compuestos modulares de sirtuina | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| CL2007002996A1 (es) | Compuestos derivados de quinolina sustituido, moduladores de los receptores x del higado; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome coronario agudo, alzheimer, diabetes y aterosclerosis. | |
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| GT200600260A (es) | Derivados de benzamida y usos relacionados con los mismos | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados | |
| UY31968A (es) | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos | |
| CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias | |
| CL2008002809A1 (es) | Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros. | |
| CO2017004994A2 (es) | Análogos de urea unidos sustituidos como moduladores de sirtuina | |
| ECSP066883A (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes | |
| AR062165A1 (es) | Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas | |
| MX2017009294A (es) | Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. | |
| MXPA06013039A (es) | El tratamiento de enfermedad respiratoria. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |